Theresa Zesiewicz

Theresa Zesiewicz, MD

Professor, Department of Neurology

Director, USF Ataxia Research Center

Movement Disorders

Contact Info 12901 Bruce B Downs Blvd.
MDC 55
Tampa FL 33612

Academic Email: tzesiewi@health.usf.edu

Academic Phone:(813) 974-5909

View My C.V.

Education

  • MD, University of Medicine and Dentistry of New Jersey, 1988

Research Interests

  • Parkinson's disease
  • Essential tremor
  • Spinocerebellar ataxia
  • Friedreich's ataxia

Memberships

  • American Board of Psychiatry and Neurology (Diplomat, 1998 - Present)
  • Parkinson's Study Group (Member, 1997 - Present)
  • American Medical Association (Member, 1995 - Present)
  • American Academy of Neurology (Fellow, 1993 - Present)
  • Movement Disorders Society (Member, 1993 - Present)

Recent Publications

  • Zesiewicz TA, Sullivan KL, Ponce de Leon M, Bennett A, Hohler AD. Quality improvement in neurology: Essential Tremor Quality Measurement Set. Neurology. , 2017. http://www.ncbi.nlm.nih.gov/pubmed/28835402
  • Zesiewicz TA, Stephenson JB, Kim SH, Sullivan KL, Jahan I, Huang Y, Salemi JL, Wecker L, Shaw JD, Gooch CL. Longitudinal gait and balance decline in Friedreich's Ataxia: A pilot study. Gait & posture. 55: 25-30, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28411441
  • Zesiewicz TA, Chriscoe S, Jimenez T, Upward J, Davy M, VanMeter S. A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease. Neurodegenerative disease management. 7(1) : 61-72, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28120630
  • Luo L, Wang J, Lo RY, Figueroa KP, Pulst SM, Kuo PH, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH. The Initial Symptom and Motor Progression in Spinocerebellar Ataxias. Cerebellum (London, England). 16(3) : 615-622, 2017. http://www.ncbi.nlm.nih.gov/pubmed/27848087
  • Zesiewicz TA, Chriscoe S, Jimenez T, Upward J, VanMeter S. A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease. Neurodegenerative disease management. 7(1) : 49-59, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28120629
  • Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, Zee PC, Gronseth GS, Gloss D, Zesiewicz T. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 87(24) : 2585-2593, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27856776
  • Patel M, Isaacs CJ, Seyer L, Brigatti K, Gelbard S, Strawser C, Foerster D, Shinnick J, Schadt K, Yiu EM, Delatycki MB, Perlman S, Wilmot GR, Zesiewicz T, Mathews K, Gomez CM, Yoon G, Subramony SH, Brocht A, Farmer J, Lynch DR. Progression of Friedreich ataxia: quantitative characterization over 5 years. Annals of clinical and translational neurology. 3(9) : 684-94, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27648458
  • Shinnick JE, Schadt K, Strawser C, Wilcox N, Perlman SL, Wilmot GR, Gomez CM, Mathews KD, Yoon G, Zesiewicz T, Hoyle C, Subramony SH, Yiu EM, Delatycki MB, Brocht AF, Farmer JM, Lynch DR. Comorbid Medical Conditions in Friedreich Ataxia: Association With Inflammatory Bowel Disease and Growth Hormone Deficiency. Journal of child neurology. 31(9) : 1161-5, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27071470
  • Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA. Emerging therapies in Friedreich's ataxia. Neurodegenerative disease management. 6(1) : 49-65, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26782317
  • Lo RY Figueroa KP Pulst SM Perlman S Wilmot G Gomez C Schmahmann J Paulson H Shakkottai VG Ying S Zesiewicz T Bushara K Geschwind M Xia G Yu JT Lee LE Ashizawa T Subramony SH Kuo SH. Depression and clinical progression in spinocerebellar ataxias. Parkinsonism Relat Disord.. 22: 87-92, 2016.
  • Dutt S, Binney RJ, Heuer HW, Luong P, Attygalle S, Bhatt P, Marx GA, Elofson J, Tartaglia MC, Litvan I, McGinnis SM, Dickerson BC, Kornak J, Waltzman D, Voltarelli L, Schuff N, Rabinovici GD, Kramer JH, Jack CR, Miller BL, Rosen HJ, Boxer AL. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 87(19) : 2016-2025, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27742814
  • Rascol O Zesiewicz T Chaudhuri KR Asgharnejad M Surmann E Dohin E Nilius S Bauer L. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. J Clin Pharmacol. : doi: 10.1002/jcph.678., 2015.
  • Eve DJ Ehrhart J Zesiewicz T Jahan I Kuzmin-Nichols N Sanberg CD Gooch C Sanberg PR Garbuzova-Davis S. Plasma Derived from Human Umbilical Cord Blood Modulates Mitogen-Induced Proliferation Of Mononuclear Cells Isolated from the Peripheral Blood of ALS Patients. Cell Transplant.. , 2015.
  • Lazaropoulos M Dong Y Clark E Greeley NR Seyer LA Brigatti KW Christie C Perlman SL Wilmot GR Gomez CM Mathews KD Yoon G Zesiewicz T Hoyle C Subramony SH Brocht AF Farmer JM Wilson RB Deutsch EC Lynch DR. Frataxin levels in peripheral tissue in Friedreich ataxia. Ann Clin Transl Neurol. 2(8) : 831-42, 2015.
  • Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism & Related Disorders. 21(5) : 514-20, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25814050
  • Puschmann A, Brighina L, Markopoulou K, Aasly J, Chung SJ, Frigerio R, Hadjigeorgiou G, Kõks S, Krüger R, Siuda J, Wider C, Zesiewicz TA, Maraganore DM. Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement. Parkinsonism & Related Disorders. 21(7) : 675-82, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25952959
  • Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, Kim SH, Sanberg CD, Vu TH, Gooch CL, Sanberg PR, Garbuzova-Davis S. Humoral factors in ALS patients during disease progression. Journal of Neuroinflammation. 12: 127, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26126965
  • Sullivan KL, Mortimer JA, Wang W, Zesiewicz TA, Brownlee HJ, Borenstein AR. Occupational Characteristics and Patterns as Risk Factors for Parkinson's Disease: A Case Control Study. Journal of Parkinson's disease. 5(4) : 813-20, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26444091
  • Zesiewicz TA, Kuo SH. Essential tremor. BMJ clinical evidence. 2015, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26678329
  • Evatt M Vaughan CP et al. Randomized, Controlled Pilot Trial of Solifenacin Succinate for Overactive Bladder in Parkinson’s Disease. Parkinsonism and Related Disorders. , 2015.
  • Moscovich M, Okun MS, Favilla C, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai V, Ying S, Zesiewicz T, Kuo SH, Mazzoni P, Bushara K, Xia G, Ashizawa T, Subramony SH. Clinical evaluation of eye movements in spinocerebellar ataxias: a prospective multicenter study. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 35(1) : 16-21, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25259863
  • Lo RY, Figueroa KP, Pulst SM, Lin CY, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai VG, Ying S, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH. Coenzyme Q10 and spinocerebellar ataxias. Movement disorders : official journal of the Movement Disorder Society. 30(2) : 214-20, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25449974
  • Lo RY, Figueroa KP, Pulst SM, Lin CY, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH. Vascular risk factors and clinical progression in spinocerebellar ataxias. Tremor and other hyperkinetic movements (New York, N.Y.). 5: 287, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25713748
  • Stephenson J, Zesiewicz T, Gooch C, Wecker L, Sullivan K, Jahan I, Kim SH. Gait and balance in adults with Friedreich's ataxia. Gait & Posture. , 2015. http://www.ncbi.nlm.nih.gov/pubmed/25662043
  • Nalls MA Pankratz N Lill CM Do CB Hernandez DG Saad M DeStefano AL Kara E Bras J Sharma M Schulte C Keller MF Arepalli S Letson C Edsall C Stefansson H Liu X Pliner H Lee JH Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group Ikram MA Ioannidis JP Hadjigeorgiou GM Bis JC Martinez M Perlmutter JS Goate A Marder K Fiske B Sutherland M Xiromerisiou G Myers RH Clark LN Stefansson K Hardy JA Heutink P Chen H Wood NW Houlden H Payami H Brice A Scott WK Gasser T Bertram L Eriksson N Foroud T Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet.. 46(9) : 989-93, 2014.
  • Tezenas du Montcel S Durr A Bauer P Figueroa KP Ichikawa Y Brussino A Forlani S Rakowicz M Schöls L Mariotti C van de Warrenburg BP Orsi L Giunti P Filla A Szymanski T, Zesiewicz CV Page 15 of 33 S Klockgether T Berciano J Pandolfo M Boesch S Melegh B Timmann D Mandich P Camuzat A; Clinical Research Consortium for Spinocerebellar Ataxia (CRC-SCA); EUROSCA network Goto J Ashizawa T Cazeneuve C Tsuji S Pulst SM Brusco A Riess O Brice A Stevanin G. Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain.. 137(9) : 2444-55, 2014.
  • Zesiewicz T, Vu T, Carranza MA, Appelbaum R, Snyder M, Staffetti JS, Allison KG, Shimberg WR, Louis ED. Unusual wrist tremor: unilateral isometric tremor? Tremor and other hyperkinetic movements (New York, N.Y.). 4, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24455450
  • Kassubek J, Chaudhuri KR, Zesiewicz TA, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. RMC Neurol. , 2014.
  • Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial Lancet Neurol. 13(7) : 676-85, 2014.
  • Kuo SH, Ashizawa T, Subramony SH. Co-Q10 and Spinocerebellar Ataxia Movement Disorders. , 2014.
  • Jones TM, Jahan I, Zesiewicz TA. Treatment of Ataxia Neurodegenerative Disease Management. , 2014.
  • Zesiewicz, TA, Kim SH, Sullivan KL. Treatment of Ataxia with Intravenous Immunoglobulin Journal of Neurology Research. , 2014.
  • Jones TM, Shaw JD, Sullivan K, Zesiewicz TA. Treatment of cerebellar ataxia. Neurodegenerative disease management. 4(5) : 379-92, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25405651
  • Tajiri N, Staples M, Kaneko Y, Kim SU, Zesiewicz TA, Borlongan CV. Autologous stem cell transplant with gene therapy for Friedreich ataxia. Medical hypotheses. 83(3) : 296-8, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24962209
  • Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA. Author response. Neurology. 82(7) : 643, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24745039
  • Benbadis SR, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson D, Vu T, Smith A, Zesiewicz T. Medical marijuana in neurology. Expert review of neurotherapeutics. 14(12) : 1453-65, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25427150
  • Kassubek J, Chaudhuri KR, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. BMC neurology. 14: 42, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24602411
  • Sullivan KL Mortimer JA Wang W Zesiewicz TA Brownlee H Borenstein AR. Early-Adult Life Correlates of in Parkinson’s Disease. Journal of Neurology Research. , 2014.
  • Corben LA Lynch D Pandolfo M Schulz JB Delatycki MB; Clinical Management Guidelines Writing Group. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis.. 9: 184, 2014.
  • Zesiewicz TA Kim SH Sullivan KL Stephenson J Jahan I Perlman SL Shaw JD Vu T Gooch CL. Treatment of Neurodegenerative Ataxias With Intravenous Immune Globulin. Journal of Neurology Research. 4(4) : 97-100, 2014.
  • Nalls MA Bras J Hernandez DG Keller MF Majounie E Renton AE Saad M Jansen I Guerreiro R Lubbe S Plagnol V Gibbs JR Schulte C Pankratz N Sutherland M Bertram L Lill CM DeStefano AL Faroud T Eriksson N Tung JY Edsall C Nichols N Brooks J Arepalli S Pliner H Letson C Heutink P Martinez M Gasser T Traynor BJ Wood N Hardy J Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Disease meta-analysis consortium. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging.. 36(3) : 1605.e7-12, 2014.
  • Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 81(5) : 463-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23897874
  • Edwards JD, Hauser RA, O'Connor ML, Valdés EG, Zesiewicz TA, Uc EY. Randomized trial of cognitive speed of processing training in Parkinson disease. Neurology. 81(15) : 1284-90, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24014503
  • Shaw JD Allison KG Staffetti JS Zesiewicz TA. Diagnosis and Treatment of Essential Tremor. Neurodegenerative Disease Management. , 2013.
  • Favilla CG, Topiol DD, Zesiewicz TA, Wagle Shukla A, Foote KD, Jacobson CE, Okun MS. Impact of discontinuing tremor suppressing medications following thalamic deep brain stimulation. Parkinsonism & related disorders. 19(2) : 171-5, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23062997
  • Zesiewicz TA, Sullivan KL, Hinson V, Stover NP, Fang J, Jahan I, Miller A, Carranza MA, Elble R. Multisite, double-blind, randomized, controlled study of pregabalin for essential tremor. Movement disorders : official journal of the Movement Disorder Society. 28(2) : 249-50, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23238907
  • Wecker L, Engberg ME, Philpot RM, Lambert CS, Kang CW, Antilla JC, Bickford PC, Hudson CE, Zesiewicz TA, Rowell PP. Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia. Neuropharmacology. 73: 75-86, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23711550
  • Seyer LA, Galetta K, Wilson J, Sakai R, Perlman S, Mathews K, Wilmot GR, Gomez CM, Ravina B, Zesiewicz T, Bushara KO, Subramony SH, Ashizawa T, Delatycki MB, Brocht A, Balcer LJ, Lynch DR. Analysis of the visual system in Friedreich ataxia. Journal of neurology. 260(9) : 2362-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23775342
  • Zesiewicz TA, Shaw JD, Allison KG, Staffetti JS, Okun MS, Sullivan KL. Update on treatment of essential tremor. Current treatment options in neurology. 15(4) : 410-23, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23881742
  • Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA. Author response. Neurology. 81(22) : 1967, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24416785
  • Lerner V, Miodownik C, Sheva B, Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 81(22) : 1967, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24276337
  • Zesiewicz TA, Martinez-Martin P. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview. Expert review of neurotherapeutics. 13(12) : 1329-42, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24236902
  • Ashizawa T, Figueroa KP, Perlman SL, Gomez CM, Wilmot GR, Schmahmann JD, Ying SH, Zesiewicz TA, Paulson HL, Shakkottai VG, Bushara KO, Kuo SH, Geschwind MD, Xia G, Mazzoni P, Krischer JP, Cuthbertson D, Holbert AR, Ferguson JH, Pulst SM, Subramony SH. Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet journal of rare diseases. 8: 177, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24225362
  • Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, McCombs A, Miller A, Zesiewicz TA. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 78(21) : 1650-4, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22573627
  • Dempsey LE, Karver MS, Labouliere C, Zesiewicz TA, De Nadai AS. Self-perceived burden as a mediator of depression symptoms amongst individuals living with a movement disorder. Journal of clinical psychology. 68(10) : 1149-60, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22814900
  • Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, Lewitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T. Reliability of a new scale for essential tremor. Movement disorders : official journal of the Movement Disorder Society. 27(12) : 1567-9, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23032792
  • Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 27(12) : 1513-1521, 2012.
  • Zesiewicz TA. Parkinson disease: the controversy of levodopa toxicity in Parkinson disease. Nature reviews. Neurology. 8(1) : 8-10, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22198404
  • Resnick AS, Okun MS, Malapira T, Smith D, Vale FL, Sullivan K, Miller A, Jahan I, Zesiewicz T. Sustained Medication Reduction Following Unilateral VIM Thalamic Stimulation for Essential Tremor. Tremor and other hyperkinetic movements (New York, N.Y.). 2, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23440408
  • Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, Chen R, Perlman SL. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology. 78(8) : 545-50, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22323747
  • Zesiewicz TA Greenstein P Sullivan KL. Double-blind, placebo-controlled trial of Varenicline in the treatment of Spinocerebellar Ataxia Type 3. Neurology.. 78(8) : 545-50, 2012.
  • Snyder M, Seyer L, Lynch DR, Resnick A, Zesiewicz TA. Cardiac dysfunction exacerbated by endocrinopathies in Friedreich ataxia: a case series. Journal of child neurology. 27(10) : 1316-9, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22408141
  • Carranza MA, Snyder MR, Elble RJ, Boutzoukas AE, Zesiewicz TA. Methodological issues in clinical drug development for essential tremor. Tremor and other hyperkinetic movements (New York, N.Y.). 2, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23440401
  • Limotai N, Go C, Oyama G, Hwynn N, Zesiewicz T, Foote K, Bhidayasiri R, Malaty I, Zeilman P, Rodriguez R, Okun MS. Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms. Journal of neurology. 258(11) : 2069-74, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21553081
  • Sanchez-Ramos J, Reimer D, Zesiewicz T, Sullivan K, Nausieda PA. Quantitative analysis of tremors in welders. International journal of environmental research and public health. 8(5) : 1478-90, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21655131
  • Friedman JH, Agarwal P, Alcalay R, Black KJ, Chou KL, Cote L, Dayalu P, Frank S, Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D, Sanchez-Ramos J, Simon DK, Simuni T, Sutton J, Tuite P, Weintraub D, Zesiewicz T. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. The International journal of neuroscience. 121(8) : 472-6, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21663381
  • Oyama G, Okun MS, Zesiewicz TA, Tamse T, Romrell J, Zeilman P, Foote KD. Delayed clinical improvement after deep brain stimulation-related subdural hematoma. Report of 4 cases. Journal of neurosurgery. 115(2) : 289-94, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21476805
  • Zesiewicz TA, Sullivan KL. Drug-induced hyperkinetic movement disorders by nonneuroleptic agents. Handbook of clinical neurology. 100: 347-63, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21496594
  • Chiong-Rivero H, Ryan GW, Flippen C, Bordelon Y, Szumski NR, Zesiewicz TA, Vassar S, Weidmer B, García RE, Bradley M, Vickrey BG. Patients' and caregivers' experiences of the impact of Parkinson's disease on health status. Patient related outcome measures. 2011(2) : 57-70, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21691459
  • Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB, Okun MS, Sullivan KL, Weiner WJ. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology. 77(19) : 1752-5, 2011. http://www.ncbi.nlm.nih.gov/pubmed/22013182
  • Cimino CR, Siders CA, Zesiewicz TA. Depressive symptoms in Parkinson disease: degree of association and rate of agreement of clinician-based and self-report measures. Journal of geriatric psychiatry and neurology. 24(4) : 199-205, 2011. http://www.ncbi.nlm.nih.gov/pubmed/22228826
  • Zesiewicz TA Elble FH Louis ED Gronseth GS Ondo WG Dewey RB Okun MS Sullivan KL Weiner WJ. Evidence-Based Guideline Update: Treatment of Essential Tremor. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.. 77(19) : 1752-5, 2011.
  • Zesiewicz TA. The controversy over levodopa toxicity. Nature Reviews (In Press). , 2011.
  • Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J, Iverson DJ, Weiner WJ. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 74(11) : 924-31, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20231670
  • Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. Neuropsychiatric disease and treatment. 6: 401-8, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20856604
  • Garbuzova-Davis S, Woods RL, Louis MK, Zesiewicz TA, Kuzmin-Nichols N, Sullivan KL, Miller AM, Hernandez-Ontiveros DG, Sanberg PR. Reduction of circulating endothelial cells in peripheral blood of ALS patients. PloS one. 5(5) : e10614, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20485543
  • Watts RL Lyons KE Pahwa R Sethi K Stern M Hauser RA Olanow W Gray AM Adams B Earl NL; 228 Study Investigators. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord. 25(7) : 858-66, 2010.
  • Simon DK Pankratz N Kissell DK Pauciulo MW Halter CA Rudolph A Pfeiffer RF Nichols WC Foroud T; Parkinson Study Group-PROGENI Investigators. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Med Genet. 1(11) : 53, 2010.
  • Zesiewicz TA, Sullivan KL, Freeman A, Juncos JL. Treatment of imbalance with varenicline Chantix(R): report of a patient with fragile X tremor/ataxia syndrome. Acta neurologica Scandinavica. 119(2) : 135-8, 2009. http://www.ncbi.nlm.nih.gov/pubmed/18771524
  • Jahan I, Hauser RA, Sullivan KL, Miller A, Zesiewicz TA. Sleep disorders in Parkinson's disease. Neuropsychiatric disease and treatment. 5: 535-40, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19898667
  • Fleischman D, Madan G, Zesiewicz TA, Fleischman M. Stiff-person syndrome: commonly mistaken for hysterical paralysis. Clinical neurology and neurosurgery. 111(7) : 644, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19473753
  • Saleh IA, Zesiewicz T, Xie Y, Sullivan KL, Miller AM, Kuzmin-Nichols N, Sanberg PR, Garbuzova-Davis S. Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. Journal of neuroimmunology. 215(1-2) : 96-101, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19682755
  • Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DR. Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). Journal of clinical neuromuscular disease. 10(4) : 191-3, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19494730
  • Zesiewicz TA, Evatt ML. Potential influences of complementary therapy on motor and non-motor complications in Parkinson's disease. CNS drugs. 23(10) : 817-35, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19739693
  • Zesiewicz TA, Sullivan KL, Hoffmann M, Benes LM, Smith DA, Ward CL, Hauser RA. Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation. European neurology. 59(3-4) : 187-9, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18230878
  • Zesiewicz TA. Low-dose topiramate (topamax) in the treatment of essential tremor. Clinical neuropharmacology. 30(4) : 247-8, 2008. http://www.ncbi.nlm.nih.gov/pubmed/17762324
  • Zesiewicz TA, Hauser RA, Freeman A, Sullivan KL, Miller AM, Halim T. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. Clinical neuropharmacology. 32(1) : 48-50, 2008. http://www.ncbi.nlm.nih.gov/pubmed/19471184
  • Zesiewicz TA, Sullivan KL. Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14). Clinical neuropharmacology. 31(6) : 363-5, 2008. http://www.ncbi.nlm.nih.gov/pubmed/19050414
  • Shimberg WR, Patel NB, Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for stiff-person syndrome: report of 2 patients. Clinical neuropharmacology. 31(5) : 301-2, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18836351
  • Espay AJ, Duker AP, Chen R, Okun MS, Barrett ET, Devoto J, Zeilman P, Gartner M, Burton N, Miranda HA, Mandybur GT, Zesiewicz TA, Foote KD, Revilla FJ. Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: preliminary observations. Movement disorders : official journal of the Movement Disorder Society. 23(16) : 2357-62, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18759339
  • Zesiewicz TA, Sullivan KL, Gooch CL. Red flags to spot the parkinsonian variant of multiple system atrophy. Nature clinical practice. Neurology. 4(11) : 596-7, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18695708
  • Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1. Clinical rheumatology. 27(3) : 389-90, 2008. http://www.ncbi.nlm.nih.gov/pubmed/17938990
  • Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Current neurology and neuroscience reports. 7(4) : 302-10, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17618536
  • Zesiewicz TA, Sullivan KL, Ward CL, Hauser RA. Tiagabine and exacerbation of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(14) : 2132-3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17663461
  • Zesiewicz TA, Ward CL, Hauser RA, Pease Campbell JA, Sullivan KL. Pregabalin (Lyrica) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(1) : 139-41, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17089400
  • Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(2) : 279-82, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17149715
  • Zesiewicz TA, Patel-Larson A, Hauser RA, Sullivan KL. Social Security Disability Insurance (SSDI) in Parkinson's disease. Disability and rehabilitation. 29(24) : 1934-6, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17852221
  • Sullivan KL, Ward CL, Hauser RA, Zesiewicz TA. Prevalence and treatment of non-motor symptoms in Parkinson's disease. Parkinsonism & related disorders. 13(8) : 545, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17188922
  • Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease. The neurologist. 13(3) : 126-32, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17495756
  • Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, Sullivan KL. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 22(11) : 1660-3, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17580330
  • Zesiewicz TA, Sullivan KL, Hauser RA. Vascular hemichorea/hemiballismus and topiramate. Movement disorders : official journal of the Movement Disorder Society. 21(4) : 581; author reply 582, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16342173
  • Zesiewicz TA, Pathak A, Sullivan KL, Shamayev M, Hauser RA. Treatment of chorea with levetiracetam. European journal of clinical pharmacology. 62(1) : 87, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16320048
  • Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 21(1) : 115-6, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16142776
  • Wolfrath SC, Borenstein AR, Schwartz S, Hauser RA, Sullivan KL, Zesiewicz TA. Use of nutritional supplements in Parkinson's disease patients. Movement disorders : official journal of the Movement Disorder Society. 21(8) : 1098-101, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16639735
  • Hauser RA, Zesiewicz TA. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology. 66(10 Suppl 4) : S58-68, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16717253
  • Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clinical neuropharmacology. 29(3) : 106-11, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16772808
  • Zesiewicz TA, Tullidge A, Tidwell J, Sullivan KL, Hauser RA. Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. Clinical neuropharmacology. 29(3) : 168-9, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16772820
  • Sullivan KL, Ward CL, Zesiewicz TA. Zonisamide-induced mania in an essential tremor patient. Journal of clinical psychopharmacology. 26(4) : 439-40, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16855471
  • Zesiewicz TA, Sullivan KL, Hauser RA. Chorea induced by lamotrigine. Journal of child neurology. 21(4) : 357; author reply 357-8, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16900938
  • Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Movement disorders : official journal of the Movement Disorder Society. 21(11) : 1998-2001, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16941461
  • Zesiewicz TA, Sullivan KL, Hauser RA. Nonmotor symptoms of Parkinson's disease. Expert review of neurotherapeutics. 6(12) : 1811-22, 2006. http://www.ncbi.nlm.nih.gov/pubmed/17181428
  • Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 66(7) : 976-82, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16606908
  • Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 66(7) : 968-75, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16606907
  • Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB, Ondo WG, Gronseth GS, Weiner WJ. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 64(12) : 2008-20, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15972843
  • Sullivan KL, Hauser RA, Louis ED, Chari G, Zesiewicz TA. Levetiracetam for the treatment of generalized dystonia. Parkinsonism & related disorders. 11(7) : 469-71, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16014339
  • Recio MV, Hauser RA, Louis ED, Radhashakar H, Sullivan KL, Zesiewicz TA. Chorea in a patient with cerebral palsy: treatment with levetiracetam. Movement disorders : official journal of the Movement Disorder Society. 20(6) : 762-4, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15747368
  • Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for the treatment of essential tremor. Movement disorders : official journal of the Movement Disorder Society. 20(5) : 640, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15756652
  • Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 20(9) : 1205-9, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15954135
  • Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser RA. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clinical neuropharmacology. 28(4) : 188-90, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16062099
  • Zesiewicz TA, Strom JA, Borenstein AR, Hauser RA, Cimino CR, Fontanet HL, Cintron GB, Staffetti JF, Dunne PB, Sullivan KL. Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey. Parkinsonism & related disorders. 10(7) : 417-20, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15465398
  • Sullivan KL, Hauser RA, Zesiewicz TA. Essential tremor. Epidemiology, diagnosis, and treatment. The neurologist. 10(5) : 250-8, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15335442
  • Zesiewicz TA, Louis ED, Sullivan KL, Menkin M, Dunne PB, Hauser RA. Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Movement disorders : official journal of the Movement Disorder Society. 19(12) : 1518-21, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15390069
  • Zesiewicz TA, Stamey W, Sullivan KL, Hauser RA. Botulinum toxin A for the treatment of cervical dystonia. Expert opinion on pharmacotherapy. 5(9) : 2017-24, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15330738
  • Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known? CNS drugs. 17(8) : 593-600, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12775195
  • Zesiewicz TA, Baker MJ, Wahba M, Hauser RA. Autonomic Nervous System Dysfunction in Parkinson's Disease. Current treatment options in neurology. 5(2) : 149-160, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12628063
  • Zesiewicz TA, Hauser RA. Depression in Parkinson's disease. Current psychiatry reports. 4(1) : 69-73, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11814399
  • Zesiewicz TA, Encarnacion E, Hauser RA. Management of essential tremor. Current neurology and neuroscience reports. 2(4) : 324-30, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12044252
  • Zesiewicz TA, Cimino CR, Malek AR, Gardner N, Leaverton PL, Dunne PB, Hauser RA. Driving safety in Parkinson's disease. Neurology. 59(11) : 1787-8, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12473772
  • Zesiewicz TA, Borra S, Hauser RA. Clozapine withdrawal symptoms in a Parkinson's disease patient. Movement disorders : official journal of the Movement Disorder Society. 17(6) : 1365-7, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12465085
  • Zesiewicz TA, Hauser RA. Phenomenology and treatment of tremor disorders. Neurologic clinics. 19(3) : 651-80, vii, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11532648
  • Zesiewicz TA, Hauser RA. Neurosurgery for Parkinson's disease. Seminars in neurology. 21(1) : 91-101, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11346031
  • Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA. Diffuse Lewy Body Disease. Current treatment options in neurology. 3(6) : 507-518, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11581527
  • Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 15(2) : 305-8, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10752581
  • Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clinical neuropharmacology. 23(2) : 75-81, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10803796
  • Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Movement disorders : official journal of the Movement Disorder Society. 15(6) : 1269-71, 2000. http://www.ncbi.nlm.nih.gov/pubmed/11104221
  • Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Movement disorders : official journal of the Movement Disorder Society. 15(4) : 658-63, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10928575
  • Hauser RA, Zesiewicz TA. Management of early Parkinson's disease. The Medical clinics of North America. 83(2) : 393-414, vi, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10093585
  • Zesiewicz TA, Hauser RA. Ropinirole in the treatment of Parkinson's disease. Expert opinion on investigational drugs. 8(5) : 697-710, 1999. http://www.ncbi.nlm.nih.gov/pubmed/15992124
  • Zesiewicz TA, Gold M, Chari G, Hauser RA. Current issues in depression in Parkinson's disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 7(2) : 110-8, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10322237
  • Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism & related disorders. 3(1) : 1-6, 1997. http://www.ncbi.nlm.nih.gov/pubmed/18591048
  • Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 12(5) : 756-9, 1997. http://www.ncbi.nlm.nih.gov/pubmed/9380061
  • Hauser RA, Zesiewicz TA. Manganese and chronic liver disease. Movement disorders : official journal of the Movement Disorder Society. 11(5) : 589, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8866509
  • Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 23(2) : 95-8, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8738919
  • Hauser RA, Zesiewicz TA. Sertraline-induced exacerbation of tics in Tourette's syndrome. Movement disorders : official journal of the Movement Disorder Society. 10(5) : 682-4, 1995. http://www.ncbi.nlm.nih.gov/pubmed/8552129
  • Hauser RA, Zesiewicz TA, Rosemurgy AS, Martinez C, Olanow CW. Manganese intoxication and chronic liver failure. Annals of neurology. 36(6) : 871-5, 1994. http://www.ncbi.nlm.nih.gov/pubmed/7998773
  • Jeret JS, Mandell M, Anziska B, Lipitz M, Vilceus AP, Ware JA, Zesiewicz TA. Clinical predictors of abnormality disclosed by computed tomography after mild head trauma. Neurosurgery. 32(1) : 9-15; discussion 15-6, 1993. http://www.ncbi.nlm.nih.gov/pubmed/8421561